Session III

Involvement of HLA-class II molecules in tumor rejection - The role of epitopes for tumor-reactive T cells

Esteban Celis, H. Kobayashi, R. Omiya, B. Sodey, E. Appella

Research output: Contribution to journalArticle

Abstract

There is little doubt that CD4 + helper T lymphocytes (HTL) play an important role in the establishment of effective antitumor immunity. During the induction phase of T cell-mediated immune responses, HTL participate in the induction of antigen-specific CD8 + cytotoxic T lymphocytes (CTL), which are the main effector immune cells against malignant cells. In addition, HTL may also be important in the maintenance of long-lived CTL responses, which is critical for the prevention of relapses and in the maintenance of immune memory. In addition, CD4 + HTL are capable of exhibiting antitumor effector function by directly recognizing and killing MHC class II + tumor cells that present HTL epitopes on their surface. For all the above reasons, the inclusion of both CTL and HTL epitopes in antitumor vaccines should be seriously considered in order to maximize the possibility of attaining optimal therapeutic effectiveness. Numerous MHC class I epitopes from tumor-associated antigens (TAA) such as HER2, CEA, MAGE and several laboratories have identified gp100 over the past 10 years. On the other hand, few MHC class II epitopes for these TAA have been defined. In our laboratory the focus has been on the identification of MHC class II-restricted epitopes using two approaches: (1) reverse immunology (predictive approach) and (2) a combined genetic/proteomic approach using tumor-reactive HTL. We will present a summary of our most recent results analyzing the strengths and weaknesses of these methods and discuss how we plan to take this knowledge into the clinic.

Original languageEnglish (US)
JournalCancer Immunology, Immunotherapy
Volume52
Issue numberSUPPL. 1
StatePublished - Dec 1 2003
Externally publishedYes

Fingerprint

Helper-Inducer T-Lymphocytes
Epitopes
T-Lymphocytes
Cytotoxic T-Lymphocytes
Neoplasms
T-Lymphocyte Epitopes
Neoplasm Antigens
CD8 Antigens
Secondary Prevention
Allergy and Immunology
Proteomics
Immunity
Vaccines
Maintenance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Session III : Involvement of HLA-class II molecules in tumor rejection - The role of epitopes for tumor-reactive T cells. / Celis, Esteban; Kobayashi, H.; Omiya, R.; Sodey, B.; Appella, E.

In: Cancer Immunology, Immunotherapy, Vol. 52, No. SUPPL. 1, 01.12.2003.

Research output: Contribution to journalArticle

@article{2c0e4ca090894a6aaa5ded49c6770630,
title = "Session III: Involvement of HLA-class II molecules in tumor rejection - The role of epitopes for tumor-reactive T cells",
abstract = "There is little doubt that CD4 + helper T lymphocytes (HTL) play an important role in the establishment of effective antitumor immunity. During the induction phase of T cell-mediated immune responses, HTL participate in the induction of antigen-specific CD8 + cytotoxic T lymphocytes (CTL), which are the main effector immune cells against malignant cells. In addition, HTL may also be important in the maintenance of long-lived CTL responses, which is critical for the prevention of relapses and in the maintenance of immune memory. In addition, CD4 + HTL are capable of exhibiting antitumor effector function by directly recognizing and killing MHC class II + tumor cells that present HTL epitopes on their surface. For all the above reasons, the inclusion of both CTL and HTL epitopes in antitumor vaccines should be seriously considered in order to maximize the possibility of attaining optimal therapeutic effectiveness. Numerous MHC class I epitopes from tumor-associated antigens (TAA) such as HER2, CEA, MAGE and several laboratories have identified gp100 over the past 10 years. On the other hand, few MHC class II epitopes for these TAA have been defined. In our laboratory the focus has been on the identification of MHC class II-restricted epitopes using two approaches: (1) reverse immunology (predictive approach) and (2) a combined genetic/proteomic approach using tumor-reactive HTL. We will present a summary of our most recent results analyzing the strengths and weaknesses of these methods and discuss how we plan to take this knowledge into the clinic.",
author = "Esteban Celis and H. Kobayashi and R. Omiya and B. Sodey and E. Appella",
year = "2003",
month = "12",
day = "1",
language = "English (US)",
volume = "52",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Session III

T2 - Involvement of HLA-class II molecules in tumor rejection - The role of epitopes for tumor-reactive T cells

AU - Celis, Esteban

AU - Kobayashi, H.

AU - Omiya, R.

AU - Sodey, B.

AU - Appella, E.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - There is little doubt that CD4 + helper T lymphocytes (HTL) play an important role in the establishment of effective antitumor immunity. During the induction phase of T cell-mediated immune responses, HTL participate in the induction of antigen-specific CD8 + cytotoxic T lymphocytes (CTL), which are the main effector immune cells against malignant cells. In addition, HTL may also be important in the maintenance of long-lived CTL responses, which is critical for the prevention of relapses and in the maintenance of immune memory. In addition, CD4 + HTL are capable of exhibiting antitumor effector function by directly recognizing and killing MHC class II + tumor cells that present HTL epitopes on their surface. For all the above reasons, the inclusion of both CTL and HTL epitopes in antitumor vaccines should be seriously considered in order to maximize the possibility of attaining optimal therapeutic effectiveness. Numerous MHC class I epitopes from tumor-associated antigens (TAA) such as HER2, CEA, MAGE and several laboratories have identified gp100 over the past 10 years. On the other hand, few MHC class II epitopes for these TAA have been defined. In our laboratory the focus has been on the identification of MHC class II-restricted epitopes using two approaches: (1) reverse immunology (predictive approach) and (2) a combined genetic/proteomic approach using tumor-reactive HTL. We will present a summary of our most recent results analyzing the strengths and weaknesses of these methods and discuss how we plan to take this knowledge into the clinic.

AB - There is little doubt that CD4 + helper T lymphocytes (HTL) play an important role in the establishment of effective antitumor immunity. During the induction phase of T cell-mediated immune responses, HTL participate in the induction of antigen-specific CD8 + cytotoxic T lymphocytes (CTL), which are the main effector immune cells against malignant cells. In addition, HTL may also be important in the maintenance of long-lived CTL responses, which is critical for the prevention of relapses and in the maintenance of immune memory. In addition, CD4 + HTL are capable of exhibiting antitumor effector function by directly recognizing and killing MHC class II + tumor cells that present HTL epitopes on their surface. For all the above reasons, the inclusion of both CTL and HTL epitopes in antitumor vaccines should be seriously considered in order to maximize the possibility of attaining optimal therapeutic effectiveness. Numerous MHC class I epitopes from tumor-associated antigens (TAA) such as HER2, CEA, MAGE and several laboratories have identified gp100 over the past 10 years. On the other hand, few MHC class II epitopes for these TAA have been defined. In our laboratory the focus has been on the identification of MHC class II-restricted epitopes using two approaches: (1) reverse immunology (predictive approach) and (2) a combined genetic/proteomic approach using tumor-reactive HTL. We will present a summary of our most recent results analyzing the strengths and weaknesses of these methods and discuss how we plan to take this knowledge into the clinic.

UR - http://www.scopus.com/inward/record.url?scp=23944488047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944488047&partnerID=8YFLogxK

M3 - Article

VL - 52

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - SUPPL. 1

ER -